Amgen's D-mab beats Fosamax in trial

In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Fosamax. D-mab, as it's known, showed greater improvement in bone mineral density in the hip and spine compared to Fosamax. "The novel means by which denosumab inhibits osteoclast-mediated bone breakdown shows the promise of RANK Ligand inhibition," said Javier San Martin, Global Development Lead for the denosumab osteoporosis program.

- see Amgen's release
- read the report for more

Related Articles:
Merck expects $1.8B hit on Fosamax
Amgen's D-mab posts positive in late-stage trial
Amgen CEO touts blockbuster potential of D-mab
Denosumab: Amgen's salvation?
Amgen touts progress in two key programs